Works matching AU LIJUN XIE

Results: 107
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Drift speed adaptive memristor model.

    Published in:
    Neural Computing & Applications, 2023, v. 35, n. 19, p. 14419, doi. 10.1007/s00521-023-08401-7
    By:
    • Li, Ya;
    • Xie, Lijun;
    • Xiao, Pingdan;
    • Zheng, Ciyan;
    • Hong, Qinghui
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34

    First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.

    Published in:
    Clinical Drug Investigation, 2021, v. 41, n. 11, p. 999, doi. 10.1007/s40261-021-01088-5
    By:
    • Wang, Lu;
    • Lu, Jinmiao;
    • Zhou, Sufeng;
    • Zhao, Yuqing;
    • Xie, Lijun;
    • Zhou, Chen;
    • Chen, Juan;
    • Ding, Sijia;
    • Xie, Daosheng;
    • Ding, Juping;
    • Yu, Qiang;
    • Shen, Hong;
    • Hao, Guangtao;
    • Shao, Feng
    Publication type:
    Article
    35

    Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study.

    Published in:
    Clinical Drug Investigation, 2020, v. 40, n. 12, p. 1155, doi. 10.1007/s40261-020-00971-x
    By:
    • Zheng, Shuai;
    • Shao, Feng;
    • Ding, Yu;
    • Fu, Zhenzhen;
    • Fu, Qi;
    • Ding, Sijia;
    • Xie, Lijun;
    • Chen, Juan;
    • Zhou, Sufeng;
    • Zhang, Hongwen;
    • Zhou, Hongwen;
    • Chen, Yang;
    • Sun, Caixia;
    • Zhu, Jing;
    • Zheng, Xuqin;
    • Yang, Tao
    Publication type:
    Article
    36
    37
    38
    39

    Mass balance, metabolic disposition, and pharmacokinetics of [<sup>14</sup>C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 6, p. 719, doi. 10.1007/s00280-020-04159-0
    By:
    • Zhou, Sufeng;
    • Liu, Wei;
    • Zhou, Chen;
    • Zhang, Lingling;
    • Xie, Lijun;
    • Xu, Zhaoqiang;
    • Wang, Lu;
    • Zhao, Yuqing;
    • Guo, Lian;
    • Chen, Juan;
    • Ding, Lieming;
    • Mao, Li;
    • Tao, Yi;
    • Zhang, Chen;
    • Ding, Sijia;
    • Shao, Feng
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50